Toronto, Ontario–(Newsfile Corp. – March 22, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“ Awakn” or the “Company“), a biotechnology company, researching, developing and delivering psychedelic therapeutics to treat addiction, is pleased to announce that they have closed a non-brokered private placement through the issuance of 2,031,250 units (the “Units“) at a price of…


Previous articleatai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
Next articleCOMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK